BiotechTube
Ohmic Biosciences

Ohmic Biosciences

Cambridge, United States· Est.

A biotech company developing Molecular Glue Degraders to target and eliminate previously undruggable disease-causing proteins.

ohmicbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

A biotech company developing Molecular Glue Degraders to target and eliminate previously undruggable disease-causing proteins.

OncologyImmunology

Technology Platform

The Ohmic Engine, an integrated platform for the discovery and optimization of Molecular Glue Degraders (MGDs), which are small molecules that induce proximity between E3 ligases and disease-causing proteins to trigger their degradation.

Opportunities

The molecular glue approach could unlock a vast landscape of intracellular targets previously considered undruggable, representing a multi-billion dollar opportunity in oncology, immunology, and beyond.
Success could lead to lucrative platform partnerships or acquisition.

Risk Factors

High technical risk in discovering effective and selective molecular glues; intense competition in the targeted protein degradation space; and the preclinical nature of the company means clinical validation is years away.

Competitive Landscape

Competes in the targeted protein degradation field against companies developing PROTACs (e.g., Arvinas) and other molecular glue specialists (e.g., Monte Rosa Therapeutics). Differentiation lies in its proprietary Ohmic Engine discovery platform focused solely on molecular glues.

More companies in United States →